(Q40852686)

24 September 2017

title

A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor (English)

1 reference

24 September 2017

M G Rosenblum

1

1 reference

24 September 2017

S A Horn

series ordinal

2

1 reference

24 September 2017

L H Cheung

series ordinal

3

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 October 2000

1 reference

International Journal of Cancer

24 September 2017

published in

1 reference

24 September 2017

volume

88

1 reference

24 September 2017

issue

2

1 reference

24 September 2017

page(s)

267-273

1 reference

An endotoxin-induced serum factor that causes necrosis of tumors

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Tumor necrosis factor stimulates ornithine decarboxylase activity in human fibroblasts and tumor target cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Resistance of HER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Potential for recombinant immunoglobulin constructs in the management of carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Amplification of a novel v-erbB-related gene in a human mammary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Effects of beta-2 microglobulin anti-sense oligonucleotides on sensitivity of HER2/neu oncogene-expressing and nonexpressing target cells to lymphocyte-mediated lysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

The use of natural interferon alpha conjugated to a monoclonal antibody anti mammary epithelial mucin (Mc5) for the treatment of human breast cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Rationale for the clinical use of immunotoxins: monoclonal antibodies conjugated to ribosome-inactivating proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Construction, characterisation and kinetics of a single chain antibody recognising the tumour associated antigen placental alkaline phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Molecular cloning and expression of a receptor for human tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Immunotoxins and recombinant toxins in the treatment of solid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Evolution of the therapeutic use of new monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Immunoglobulin-cytokine fusion molecules: the new generation of immunomodulating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Prognostic factors in early breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Experimental immunotherapy of breast cancer using alpha interferon conjugated to monoclonal antibody Mc5

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Recombinant antibody fusion proteins for cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0215%2820001015%2988%3A2%3C267%3A%3AAID-IJC19%3E3.0.CO%3B2-G

10.1002/1097-0215(20001015)88:2<267::AID-IJC19>3.0.CO;2-G

21 January 2018

Identifiers

DOI

1 reference

release_3yd7grzbqndbfe44srv6bwqm7m

24 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3yd7grzbqndbfe44srv6bwqm7m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference